A high percentage of women receiving 5 mg. of norethynodrel with mestranol in cyclic fashion for contraception have decreased glucose tolerance. Ten per cent have elevated fasting levels, 20 per cent have elevated one-hour levels and 46 per cent have elevated two-hour levels (greater than our normal mean + 2 standard deviations of 105, 156 and 113 mg./lOO ml., respectively). The incidence of abnormal glucose tolerance is greater in women with a family history of diabetes than in those without a history.
In some women taking the ovulatory suppressant, norethynodrel and mestranol,* the plasma proteinbound iodine and the plasma cortisol levels may be elevated. 2 - 3 These changes do not result in any clinical evidence of thyroid or adrenocortical hyperactivity and are similar to those seen during administration of estrogens or in pregnancy. We have found a metabolic change, decreased glucose tolerance, in a high percentage of women taking this drug.
MATERIALS AND METHODS
The patients were receiving norethynodrel and mestranol in the usual cyclic manner for contraception, 5 mg. a day for twenty days beginning on the fifth day of each menstrual cycle.
They were referred at random from the gynecology clinic. Of the fifty-nine women examined, fifty-one were of Puerto Rican origin. Their intake was high in carbohydrate, containing at least 250 to 350 gm. a day, and * Supplied as Enovid from G. D. Searle and Company, and containing in each 5 mg. tablet of norethynodrel (17 alphaethynyl-17 hydroxy-5-(io)-estren-3-one), and .075 mg. of mestranol (ethynylestradiol 3-methyl ether) .
From the Department of Medicine, New York University Medical Center and Bellevue Hospital, New York. no preparatory diet was used for the glucose tolerance test. The latter was performed without reference to the time of cyclic treatment. One hundred grams of glucose by mouth was given as the test dose, and venous blood was analyzed for glucose at one and two hours by the Nelson-Somogyi method. 4 Serum protein electrophoresis was done, and plasma protein-bound iodine, cholesterol, triglycerides and free fatty acid were measured; these data will be reported in a later communication.
Plasma SGOT, SGPT and alkaline phosphatase were measured but are not reported because the values were all within normal range.
RESULTS
The glucose tolerance tests in the fifty-nine women taking the drugs are shown in figure 1. It is apparent that glucose tolerance is decreased in a high percentage of patients. The mean age of the entire group is twentynine years. In this age group our normal values in nonpregnant subjects are: fasting blood glucose 81 ± 12 mg. per 100 ml. (Standard Deviation, S.D.), one-hour 102 ± 27 mg. per 100 ml., two-hours 81 ± 16 mg. per 100 ml. -corresponding closely to those of CameriniDavalos et al. 5 If the mean -\-2 S.D. is taken as the upper limit of normal (figure 1), 10 per cent had elevated fasting levels, 20 per cent had elevated one-hour levels and 46 per cent had elevated two-hour levels.
The incidence of abnormal glucose tolerance appeared to be greater in the women with a family history of diabetes than in those without. Of twelve patients with such a history ( had a history of renal glycosuria during the last trimester of her first pregnancy four years before, with a fasting blood glucose of 85 mg. per 100 ml. and a two-hour postprandial level of 80 mg. per 100 ml. Glycosuria was also noted one year later during the last trimester of her second pregnancy. Norethynodrel with mestranol was started just after her second pregnancy. Thirty-four months later, when she developed pruritis, polydipsia and polyuria, she was found to have postprandial blood glucose levels of 150 to 280 mg. per 100 ml. Since then she had been taking 2 gm. of tolbutamide daily. Most of the women studied had been taking the ovulatory suppressant for two years or longer. Decreased glucose tolerance was present in one woman, however, after only five months of treatment (L.T., no. 46, table 1).
No definite conclusions regarding obesity could be made. Three of the women with a family history of diabetes were moderately obese (more than 15 per cent of ideal body weight), and all three had distinctly abnormal glucose tolerance. Several of the women without a family history were obese, but no consistent pattern of response was observed, in that some of these had decreased glucose tolerance and some did not. of norethynodrel and mestranol on carbohydrate metabolism. In experimental diabetes, estrogens have a variable effect depending upon the dosage and duration of treatment, the animal used, and the diet. 6 In subtotally pancreatectomized rats, estrogens produce an early increase and a later reduction in the diabetes. In forcefed normal and alloxan-diabetic rats, estrogens temporarily increase glycosuria and hyperglycemia. In all of these experiments progesterone in moderate doses is inactive. Estradiol benzoate, diethylstilbestrol and large doses of norethynodrel (5 mg. a day for five days) increase the fasting blood glucose in intact rats. 7 In view of these experiments it seems likely that the decrease in glucose tolerance observed in these patients is associated with the estrogenic activity of the drug. Though the amount of mestranol administered may seem small, it is sufficient to maintain cornification of the vaginal epithelium in castrates or women with ova- rian deficiency, and to increase the plasma protein-binding of thyroxine; 2 and as little as o.oi mg. of ethinyl estradiol a day raises the protein-bound iodine level in women treated for one to eleven months. 8 Moreover, mestranol is not the sole estrogenic substance in the drug, since a large part of norethynodrel is converted in vivo to substances having estrogenic activity. 9 Should it be confirmed that estrogens are responsible for decreasing glucose tolerance in man, then the belief, long held, that deficiency of estrogen is an important factor in the increased frequency of diabetes among post-menopausal women would have to be changed.
It seems reasonable to associate the change in glucose tolerance with the "pseudo-pregnancy" produced by the drug. There is no unanimity of opinion about the frequency of diabetes in pregnancy, 10 but investigators have found an incidence of abnormal glucose tolerance tests ranging from io to 8i per cent.
11 ' 12 Using a twohour blood glucose of 120 mg. per 100 ml. as the upper limit of normal, Wilkerson 13 estimated an incidence of 6.2 per cent abnormal tests, increasing with the progression of pregnancy. Thirty-four per cent of our entire group had two-hour blood levels above 120 mg. per 100 ml. It should be mentioned that others have just reported a decrease in glucose tolerance in six of nine patients with rheumatoid arthritis treated with large doses of the drug in question (15-50 mg. a day) for eight to 300 days. 14 It is generally agreed that the incidence of abnormal glucose tolerance is higher in those pregnant women predisposed to diabetes by virtue of family history. Our results are compatible with this observation.
Thirty to 66 per cent of women with abnormal glucose tolerance during pregnancy are said to develop permanent diabetes in one to seven years. 10 It is obviously important to find out if women with decreased glucose tolerance during treatment with norethynodrel and mestranol will later become permanently diabetic. If this happens, then treatment with this drug may constitute a stress that would be useful in detecting individuals who may be predisposed to diabetes. These studies, as well as others designed to show how soon after administration of the drug abnormal glucose tolerance appears, are now in progress.
The mechanism of the decrease in glucose tolerance is obscure, and there are many factors that might account for this. Two possibilities that are suggested by recent observations and that can be approached experimentally are: norethynodrel with mestranol may increase the plasma protein-binding of insulin, as it does that of thyroxine and of corticosteroids, 2 ' 3 and thus render it inactive; 15 the estrogens may stimulate pituitary ACTH secretion in man as they do in rats. 16 That estrogens potentiate the diabetogenic effect of adrenal corticosteroids is shown by the enhanced glucosuric effect of hydrocortisone in the presence of estrogen. 17 
SUMMARIO IN INTERLINGUA

Tolerantia pro Glucosa in Feminas Recipiente un A gent e de Suppression Ovulatori
Un alte procentage de feminas recipiente 5 mg de norethynodrel con mestranol a base cyclic pro objectivos de contraception ha reducite tolerantias pro glucosa. Dece pro cento ha elevate nivellos in stato jejun, 20 pro cento ha elevate nivellos post un hora, e 46 pro cento ha elevate nivellos post duo horas (i.e., in supra de nostre normal valor medie -(-2 deviationes standard de 105, 156, e 113 mg per 100 ml, respectivemente). Le incidentia de anormal tolerantia pro glucosa es plus grande in feminas con antecedentes familial de diabete que in feminas sin tal antecedentes.
II pare plausibile associar le alteration del tolerantia pro glucosa con le "pseudo-pregnantia" que es le effecto del pharmaco. Multe feminas qui disveloppa un reducite tolerantia pro glucosa in pregnantias natural disveloppa subsequentemente un diabete permanente. Si isto es ver etiam pro le feminas qui manifesta un reducite tolerantia pro glucosa durante que illas recipe le mentionate pharmaco, alora il es possibile que iste responsa distingue le stato prediabetic. Part of the data reported in this article have been published in abstract. 1 
